A.臨床開発に最適な複方(S)を選択する。 B.人体の安全性、有効性と選択性を評価するために、I期、II期とIII期の臨床試験を行った。 C.規制部門の承認を受ける。
化学原料を購入する必要がある場合は、 要求情報を送信してください最新の見積りを入手してください。
3-MERCAPTO-3-METHYL-BUTYRYL-TYR-PHE-VAL-ASN-CYS-PRO-D-ARG-GLY-NH2
N-(2-amino-6-(4-methoxyphenyl)pyrimidin-4-yl)methanesulfonamide
(2S)-cyclohexyl({[5-(2,6-dimethoxyphenyl)-1-(4-fluorophenyl)-1H-pyrazol-3-yl]carbonyl}amino)ethanoic acid
tert-butyl (S)-3-((5-bromo-2-chloropyrimidin-4-yl)amino)piperidine-1-carboxylate
bis(benzonitrile)palladium(II) dichloride
C16H18N4O2
4-[(2-methoxyethoxy)methyl]benzoic acid
1,2,3,4-tetrakis-O-(3,4,5-trihydroxybenzoyl)-alpha-D-glucopyranose
C21H21BrN2O2
5-BROMO-2-[(4-CHLOROBENZYL)OXY]BENZALDEHYDE
3-{[(1S)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione
N-[4-(6-chloro-2-isopropylamino-pyrimidin-4-ylsulfamoyl)-phenyl]-acetamide
methyl (1α,3α,4β)-4-[(tert-butoxycarbonyl)amino]-3-hydroxycyclohexanecarboxylate
4-phenoxy-2-phenylquinazoline
1H-Indazole-3-carboxamide, N-(2-methylphenyl)-
Quinoline-5-sulfonyl Chloride
1-cyclopropyl-3-(4-(5-(2,2-difluoropropyl)-6a-methyl-6-oxo-5,6,6a,7,9,10-hexahydro[1,4]oxazino[3,4-h]pteridin-2-yl)phenyl)urea
6-(2,6-DICHLOROPHENYL)-8-METHYL-2-METHYLSULFONYL-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE
N-phenylsulfonyl-5-hydroxy-6-methoxy-1H-indole
trifluoroacetic acid
(2S,3S), 2-[4-methoxybenzylsulfanyl], 3-tertiobutyloxycarbonylamino-hexane-dioic acid 1-allyl ester, 6-tertiobutyl ester
2H-Cyclopenta[b]furan-2-carbonitrile,5-(acetyloxy)hexahydro-(9CI)